随机化和统计功效：试验可重复性的关键（即使对于罕见癌症也是如此）。
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).
机构信息
D.O., Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, Michigan 48106, USA.
出版信息
Oncologist. 2012;17(9):1129-32. doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.
Abstract
This article comments on the importance of randomization and statistical power in clinical trials.
摘要
本文评论了随机化和临床试验统计功效的重要性。
相似文献
1
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).
Oncologist. 2012;17(9):1129-32. doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.
2
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Cell Cycle. 2017 Jun 3;16(11):1063-1069. doi: 10.1080/15384101.2017.1314406. Epub 2017 Apr 20.
3
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Anticancer Drugs. 2007 Jul;18(6):745-7. doi: 10.1097/CAD.0b013e32805f8f0c.
4
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Oncologist. 2012;17(9):1213-20. doi: 10.1634/theoncologist.2011-0467. Epub 2012 Aug 20.
5
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
J Clin Oncol. 2002 Jun 15;20(12):2824-31. doi: 10.1200/JCO.2002.11.050.
6
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Intern Med. 2017 Aug 15;56(16):2145-2149. doi: 10.2169/internalmedicine.6965-15. Epub 2017 Aug 1.
7
Gemcitabine/docetaxel--welcome to a new standard.
Gynecol Oncol. 2008 Jun;109(3):313-5. doi: 10.1016/j.ygyno.2008.04.025.
8
Novel approaches to treatment of leiomyosarcomas.
Curr Oncol Rep. 2011 Aug;13(4):316-22. doi: 10.1007/s11912-011-0173-0.
9
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Int J Clin Oncol. 2014 Oct;19(5):897-905. doi: 10.1007/s10147-013-0627-5. Epub 2013 Oct 24.
10
Adult primary pleomorphic leiomyosarcoma of forearm with axillary lymph node metastasis: a case report and literature review.
J Cancer Res Ther. 2012 Jul-Sep;8(3):448-50. doi: 10.4103/0973-1482.103532.
引用本文的文献
1
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.
Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164.
2
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489.
3
Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.
J Clin Epidemiol. 2018 Nov;103:1-9. doi: 10.1016/j.jclinepi.2018.06.012. Epub 2018 Jul 2.
本文引用的文献
1
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Oncologist. 2012;17(9):1213-20. doi: 10.1634/theoncologist.2011-0467. Epub 2012 Aug 20.
2
Drug development: Raise standards for preclinical cancer research.
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
3
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Oncologist. 2012;17(3):321. doi: 10.1634/theoncologist.2010-0265. Epub 2012 Feb 23.
4
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.
5
Outcome--adaptive randomization: is it useful?
J Clin Oncol. 2011 Feb 20;29(6):771-6. doi: 10.1200/JCO.2010.31.1423. Epub 2010 Dec 20.
6
Adaptive clinical trials: the promise and the caution.
J Clin Oncol. 2011 Feb 20;29(6):606-9. doi: 10.1200/JCO.2010.32.2685. Epub 2010 Dec 20.
7
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Cancer Chemother Pharmacol. 2008 Dec;63(1):149-55. doi: 10.1007/s00280-008-0723-9. Epub 2008 Mar 20.
8
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
Oncologist. 2007 Aug;12(8):999-1006. doi: 10.1634/theoncologist.12-8-999.
9
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
J Clin Oncol. 2007 Jul 1;25(19):2755-63. doi: 10.1200/JCO.2006.10.4117.
10
Practical Bayesian adaptive randomisation in clinical trials.
Eur J Cancer. 2007 Mar;43(5):859-66. doi: 10.1016/j.ejca.2007.01.006. Epub 2007 Feb 16.
Zotero 插件